Volume 29, Issue 1 (3-2005)                   Research in Medicine 2005, 29(1): 19-21 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Efficacy of combined Xeloda/Taxotere regimen in metastatic breast cancer. Research in Medicine. 2005; 29 (1) :19-21
URL: http://pejouhesh.sbmu.ac.ir/article-1-52-en.html
Abstract:   (13668 Views)
Background: Taxotere and Xeloda have been previously shown to be effective in metastatic breast cancer when prescribed as a single drug in addition, some studies have demonstrated their synergism in breast cancer. During the present study, we have used a combined Xeloda/Taxotere regimen in metastatic breast cancer patients who have never been on either drug. Materials and methods: Twelve breast cancer patients who have been on anthracycline regimen and had at least one measurable metastatic site were included. They were put on the following regimen: Taxotere 75mg/m2 for the first day and Xeloda 1000mg/m2 twice a day for 14 days. This protocol was repeated 3 times with 3 weeks interval between each phase. Metastatic sites were reevaluated following the course of therapy. Results: Of 12 patients, 4 have shown a complete response and 3 partial response. Myelosuppression was the most frequent drug side effect presenting in 5 patients. Conclusion: Combined regimen of Xeloda/Taxotere was found to be more effective than the single drug regimen. The side effects are acceptable.
Full-Text [PDF 104 kb]   (2721 Downloads)    
Type of Study: General | Subject: Interdisciplinary (Educational Management, Educational research, Statistics, Medical education
Received: 2003/11/27 | Published: 2005/03/15

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This Journal is licensed under a Creative Commons Attribution 4.0 International License  | Research in Medicine

Designed & Developed by : Yektaweb